Compugen Ltd. — FY2020 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone 2020 fourth-quarter filing. Financial statements are prepared under U.S. GAAP and presented in U.S. dollars.
Business context
Compugen is a clinical-stage immuno-oncology company using computational discovery platforms to identify drug targets and develop therapeutic candidates. Its clinical-stage programs are COM701 (PVRIG), COM902 (TIGIT), and Bayer-partnered BAY 1905254 (ILDR2). The company has no products approved for sale and relies on collaborations, licensing and potential future milestones and royalties for revenue.
Key financial metrics
| US$ millions, except per-share data | 2020 | 2019 | Change / context |
|---|---|---|---|
| Revenue | 2.0 | 0 | 2020 revenue was an AstraZeneca preclinical milestone. |
| Operating expenses | 33.4 | 28.9 | Up 16%; R&D expense rose to 22.8 from 19.8. |
| Operating loss | (31.5) | (28.9) | Loss widened. |
| Financial and other income, net | 1.8 | 0.8 | Increase mainly reflected interest income on higher cash and deposit balances. |
| Net loss | (29.7) | (27.3) | Loss widened; basic and diluted loss per share improved to $(0.37) from $(0.43). |
| Net cash used in operating activities | (28.3) | (27.9) | Higher clinical-trial and manufacturing costs, partly offset by prior cost reductions. |
| Cash, cash equivalents, restricted cash and short-term deposits | 124.4 | 43.9 | Year-end balance; company separately reports $123.8 million of cash, cash equivalents and short-term deposits. |
| Total assets / shareholders’ equity | 138.3 / 119.8 | 53.8 / 38.3 | Increase primarily reflected 2020 equity financing and exercises. |
Gross profit was $1.9 million in 2020; cost of revenue was $0.06 million, mainly IIA royalties. Accumulated deficit reached $387.9 million. The filing does not report conventional borrowings; liabilities primarily include payables, lease liabilities, severance and deferred R&D participation. Operating lease obligations totaled $3.2 million on the balance sheet.
Material changes and financing
- Revenue fell from $17.8 million in 2018 to zero in 2019 and $2.0 million in 2020. The 2018 total included a $10 million AstraZeneca upfront payment and a $7.8 million Bayer milestone.
- R&D expense increased 15% in 2020, driven by Phase 1 studies, manufacturing and related activities. Management expected R&D expense to rise about 50% in 2021 as clinical trials expanded, representing approximately 75% of planned operating expenses.
- The March 2020 public offering generated $74.1 million net. Option and warrant exercises generated approximately $34.2 million. Shares outstanding increased from 67.9 million at year-end 2019 to 83.7 million at year-end 2020.
- Net cash used in investing activities was $82.2 million in 2020, largely reflecting the placement of higher cash balances into bank deposits; net cash provided by financing activities was $108.5 million.
Outlook, risks and notable items
- Management expected existing cash and short-term deposits to fund operations through 2023 at the then-current annual spending level. It cautioned that expanded clinical trials and higher spending could shorten the runway; additional financing may be needed.
- Key execution risks include clinical safety, efficacy and enrollment; dependence on COM701 and, to a lesser extent, COM902; third-party manufacturing and trial providers; collaboration and licensing outcomes; and competition in immuno-oncology. Preliminary COM701 results are not definitive evidence of efficacy or approval prospects.
- As of the December 14, 2020 data cutoff, the company reported preliminary COM701 activity in small Phase 1 cohorts, including a complete response and a partial response in the combination dose-escalation arm. These are early, non-confirmatory findings.
- COVID-19 could disrupt staff, suppliers, manufacturing and clinical trials. Compugen also faces Israeli shekel exposure: the U.S. dollar depreciated 7.0% against the shekel in 2020; management estimated a 10% dollar devaluation would cause about $1.3 million of exchange losses.
- Potential IIA royalties and related obligations were approximately $9.4 million at year-end, contingent on revenue from funded research. IIA rules may also restrict transfer of funded know-how and manufacturing outside Israel.
- Two parties filed oppositions in October 2020 seeking revocation of a European anti-PVRIG patent. The filing reported no material pending legal proceedings. The company reported effective internal controls; the auditor gave unqualified opinions on the financial statements and internal controls. Accrued clinical and preclinical trial expenses were identified as a critical audit matter.
Investor verification priorities
- Confirm the cash and deposit definitions behind the $124.4 million selected-data figure versus the $123.8 million liquidity figure, and reassess runway against planned trial spending.
- Review full COM701 and COM902 trial data, enrollment, safety findings, and whether preliminary signals persist in larger cohorts.
- Check the timing and conditions of collaboration milestones, royalty economics, and the status of the AstraZeneca and Bayer programs.
- Assess dilution and potential future capital needs, including outstanding options and warrants, alongside the 2020 share issuance.
- Monitor the anti-PVRIG patent opposition and the potential IIA royalty and know-how transfer obligations.